Ventris Medical Earns FDA 510(k) for Connext Surgical Matrix

Ventris Medical was granted FDA 510(k) clearance to market Connext Surgical Matrix, a precisely engineered collagen wound dressing designed to significantly improve the wound healing environment and help mitigate common complications. This offering aims to support the wound healing cascade, which can reduce the incidence of infection, seromas, hematomas, and drainage following surgical procedures.

Sourced from bovine achilles tendon, the highly purified Type 1 collagen used in the matrix leverages robust biological properties known to support tissue regeneration and repair. This specific collagen source directly contributes to the natural healing processes within the wound bed, fostering an optimal environment for normal re-epithelialization.

Its advanced processing and formulation features a uniform particle size, a carefully maintained pH, and low endotoxin levels, all crucial attributes that make it amenable for use in any spinal fusion procedure. The particle size and low pH allows rapid, uniform absorption of wound exudates, while the low endotoxin level ensures its suitability and safety for use in highly sensitive surgical environments.

Its application is facilitated by a proprietary bellow spray system, allowing for precise and consistent deployment across even the most challenging wound bed anatomies.

“The introduction of our new Connext Surgical Matrix is a direct response to critical unmet needs within the medical community,” said Russell Cook, CEO of Ventris Medical, “Connext offers a significant leap forward in patient care by intentionally targeting the biology of the surgical wound environment, which supports normal healing processes. The new design is intended to minimize common postoperative complications such as infection, seromas, hematomas, and drainage.”

Source: Ventris Medical